Items Tagged ‘Acalabrutinib’

August 9th, 2017

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma

By

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. The Breakthrough Therapy Designation […]

View full entry

Tags: Acalabrutinib, Bruton tyrosine kinase, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


December 17th, 2015

ACP-196 Bruton’s Tyrosine Kinase Inhibitor Safe and Effective for Chronic Lymphocytic Leukemia

By

Clinical results published in the New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) is well tolerated and yields high response rates that are durable in patients with chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- […]

View full entry

Tags: Acalabrutinib, ACP-196, Chronic, Chronic Lymphocytic Leukemia, CLL, Leukemia, News